OptimizeRx (NASDAQ:OPRX) Price Target Raised to $12.50

OptimizeRx (NASDAQ:OPRX) had its price target lifted by Stifel Nicolaus from $8.00 to $12.50 in a research note published on Tuesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Other equities analysts have also issued reports about the stock. B. Riley raised shares of OptimizeRx to a “strong-buy” rating in a research report on Wednesday, March 12th. JMP Securities raised their price target on shares of OptimizeRx from $11.00 to $14.00 and gave the stock a “market outperform” rating in a research report on Tuesday. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $10.38.

OptimizeRx Price Performance

Shares of OPRX opened at $10.65 on Tuesday. The firm has a market capitalization of $196.95 million, a PE ratio of -8.01 and a beta of 1.28. The company’s 50-day moving average is $8.59 and its 200-day moving average is $6.43. OptimizeRx has a fifty-two week low of $3.78 and a fifty-two week high of $13.33. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.23 and a quick ratio of 3.23.

OptimizeRx (NASDAQ:OPRX) last issued its quarterly earnings data on Monday, May 12th. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.19. The company had revenue of $21.93 million for the quarter, compared to analyst estimates of $18.69 million. OptimizeRx had a negative net margin of 27.41% and a negative return on equity of 4.92%. Equities analysts forecast that OptimizeRx will post -0.33 EPS for the current year.

Insiders Place Their Bets

In related news, Director James Paul Lang purchased 321,408 shares of OptimizeRx stock in a transaction dated Friday, March 14th. The shares were bought at an average cost of $7.60 per share, for a total transaction of $2,442,700.80. Following the purchase, the director now owns 389,452 shares in the company, valued at approximately $2,959,835.20. This trade represents a 472.35% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 6.10% of the company’s stock.

Institutional Investors Weigh In On OptimizeRx

A number of hedge funds have recently made changes to their positions in the stock. Whetstone Capital Advisors LLC boosted its stake in shares of OptimizeRx by 11.7% in the 1st quarter. Whetstone Capital Advisors LLC now owns 1,508,303 shares of the company’s stock valued at $13,062,000 after purchasing an additional 157,880 shares in the last quarter. Royce & Associates LP acquired a new stake in shares of OptimizeRx in the 4th quarter valued at approximately $5,198,000. Blair William & Co. IL boosted its stake in shares of OptimizeRx by 4.9% in the 1st quarter. Blair William & Co. IL now owns 631,031 shares of the company’s stock valued at $5,465,000 after purchasing an additional 29,648 shares in the last quarter. Kennedy Capital Management LLC boosted its stake in shares of OptimizeRx by 57.8% in the 4th quarter. Kennedy Capital Management LLC now owns 594,000 shares of the company’s stock valued at $2,887,000 after purchasing an additional 217,676 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of OptimizeRx by 9.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 444,167 shares of the company’s stock valued at $2,159,000 after purchasing an additional 39,740 shares in the last quarter. 76.47% of the stock is currently owned by institutional investors and hedge funds.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.